The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy
Open accessAbstract
IMPORTANCE: Vitiligo is a common condition that is often emotionally devastating for patients. At present, no reliably effective treatments are available. OBSERVATIONS: Recent advances in the understanding of the pathogenesis of vitiligo suggest that Janus kinase inhibitors may be a therapeutic option. We report a case of generalized vitiligo for which treatment with tofacitinib citrate, an oral Janus kinase 1/3 inhibitor, resulted in significant repigmentation. CONCLUSIONS AND RELEVANCE: The results suggest that tofacitinib and other Janus kinase inhibitors may be effective in the treatment of vitiligo. Additional studies will be needed to confirm their efficacy and to explore their safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
JAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927
Rashighi, M., Agarwal, P., Richmond, J. M., Harris, T. H., Dresser, K., Su, M.-W., Zhou, Y., Deng, A., Hunter, C. A., Luster, A. D., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007811 · Cited by 518
Harris, J. E., Harris, T. H., Weninger, W., John Wherry, E., Hunter, C. A., & Turka, L. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.463 · Cited by 389
Treatment of Vitiligo With UV-B Radiation vs Topical Psoralen Plus UV-A
Westerhof, W. (1997) · Archives of Dermatology · doi:10.1001/archderm.133.12.1525 · Cited by 370
Papp, K. A., Menter, A., Strober, B., Langley, R. G., Buonanno, M., Wolk, R., Gupta, P., Krishnaswami, S., Tan, H., & Harness, J. A. (2012) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2012.11168.x · Cited by 338
Craiglow, B. G., & King, B. A. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.260 · Cited by 223
Self-citationPorts, W. C., Khan, S., Lan, S., Lamba, M., Bolduc, C., Bissonnette, R., & Papp, K. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12266 · Cited by 204
Nutritional deficiency and the skin
Miller, S. J. (1989) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(89)70144-4 · Cited by 176
Boy, M. G., Wang, C., Wilkinson, B. E., Chow, V. F.-S., Clucas, A., Krueger, J. G., Gaweco, A. S., Zwillich, S. H., Changelian, P. S., & Chan, G. L. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.25 · Cited by 142
Strober, B. E., Buonanno, M., Clark, J. D., Kawabata, T. T., Tan, H., Wolk, R. A., Valdez, H., Langley, R. G. B., Harness, J. A., Menter, A., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12517 · Cited by 99
Cited by
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.201 · Cited by 1,266
Bergqvist, C., & Ezzedine, K. (2020) · Dermatology · doi:10.1159/000506103 · Cited by 799
CD49a Expression Defines Tissue-Resident CD8 + T Cells Poised for Cytotoxic Function in Human Skin
Cheuk, S., Schlums, H., Gallais Sérézal, I., Martini, E., Chiang, S. C., Marquardt, N., Gibbs, A., Detlofsson, E., Introini, A., Forkel, M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.01.009 · Cited by 678
“Interestingly, a case report suggests clinical efficacy of toficitinib, a small molecule inhibitor of JAK1 and JAK3, on vitiligo (Craiglow and King, 2015).”
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Schwartz, D. M., Bonelli, M., Gadina, M., & O'Shea, J. J. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.167 · Cited by 648
Erratum: JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Schwartz, D. M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., & O'Shea, J. J. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.267 · Cited by 394
Metadata
- Authors
- Craiglow, B. G., & King, B. A.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2015-10-01
- Volume
- 151
- Issue
- 10
- Pages
- 1110
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W1494514268
- Cited by
- 259
- References
- 12
- FWCI
- 12.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. https://app.cochat.ai/papers/10.1001/jamadermatol.2015.1520
- The paper
- Craiglow, B. G., & King, B. A. (2015). Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2015.1520
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
